Original Report

A qualitative exploration of supports and unmet needs of diverse young women with breast cancer


 

Background Young women with breast cancer face different challenges than those faced by older women because of their age and life stage, yet few studies have focused on the different challenges faced by women from diverse populations.
Objective To explore existing supports that are important during diagnosis and treatment and the unmet needs for information and support in young women with breast cancer.
Methods We conducted 20 semistructured interviews in English with women aged 42 or younger who had been diagnosed with stage I-III invasive breast cancer within the previous 4 years. We recorded and transcribed the interviews and used collaborative group immersion/ crystallization to analyze data, identify emergent themes, and determine if there were differences by race/ethnicity.
Results 20 participants, recruited from 9 US states and Canada, were interviewed, of whom 25% were Hispanic, 15% were black, 50% were white and non-Hispanic, and 10% were another race/ethnicity. Faith and/or spirituality and family were reported as important sources of support by many of the participants. Most of them lamented the inadequacy of their connections with other young survivors and also of supports for their family. Some recommended that young patients be provided with more information about: treatment-related physical and emotional changes; fertility and menopause; relationships after cancer; navigating work challenges; and transitioning into survivorship. None of these supports or recommendations was limited to a specific race/ethnicity or geographic region.
Limitations Small sample size, exclusion of non-English speakers. Conclusions Key informant interviews of young breast cancer survivors identified similar needs for education and support across various races/ethnicities and geographies.
Funding/sponsorship Supported by an ASCO Cancer Foundation/Susan G Komen for the Cure Improving Cancer Care Grant (PI: Partridge) and by NIH 5K05 CA124415-05 (PI: K Emmons).

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

For metastatic breast cancer, adding pertuzumab not cost-effective
Breast Cancer ICYMI
DCIS: Recurrence risk rises after forgoing radiotherapy
Breast Cancer ICYMI
Fulvestrant may best anastrozole as first-line therapy
Breast Cancer ICYMI
More genomic instability found in breast tumors of black women
Breast Cancer ICYMI
LCIS: 2% annual cancer risk, less than 1% with chemoprevention
Breast Cancer ICYMI
DCIS recurrences have declined significantly
Breast Cancer ICYMI
Radiation + lumpectomy tied to increased survival in older women with TNBC
Breast Cancer ICYMI
Molecular Imaging of ER Status in Breast Cancer: A Preclinical Study
Breast Cancer ICYMI
Implementation of the 21-Gene Risk Score Assay, OncotypeDx Breast, Within the VA
Breast Cancer ICYMI
Testing for BRCA1/BRCA2 in the VA
Breast Cancer ICYMI